I use Bloomberg,com watch list function - it seems to be the...

I use Bloomberg,com watch list function - it seems to be the best at providing accrurate fully diluted market cap data

AGH is certainly making progress with customers and the quarterly data shows consistent growth

But the bottom line is that March quarter revenue, while up an excellent 64%, was still only $135,000 supporting the 95 Mill market cap

If you look at any of the other stocks generating revenues you will see that appears to be a very opptimistic market cap (presumably pricing in upside from EU opportunities)

Need more data in the next two days from all the outstanding 4C's but here is a rough guide (not all the numbers are exactly up to date)

Company	Share Price	Fully diluted Shares	AUD Mkt Cap	Ratio (mkt cap / revenue)	Target ratio	Target Price	March 2019	Qtr on Qtr Growth	12/2018
BOD AUSTRALIA	$0.31	52.5	19.4	6.9			$0		$704
ZELDA THERAPEUTICS			41.0				$0	0.0%	$0
MGC PHARMA			51.0	17.1			$0		$744
CRESO PHARMA	$0.45		60.0	68.5			$0		$219
MEDLAB CLINICAL	$0.37	213.9	79.1	15.6			$0		$1,269
ALTHEA	$0.47	237.5	95.0	175.9			$135	64.6%	$82
AUSCANN	$0.40	324.5	129.8	0.0			$0	0.0%	$0
CANN GROUP			346.0	0.0			$0	0.0%	$1
ELIXINOL	$5.40	114.8	620.0	19.1			$8,096	-28.6%	$11,334
Eco Fibre	$1.50	472.0	708.0	19.0			$9,308	21.7%	$7,650
									$22,003